Twist Bioscience Corp Insider Trading Activity

Twist Bioscience Corp President and COO Patrick John Finn reported an open-market sale of 4,294 shares of common stock at an average price of $46.7098 per share.

Rhea-AI Filing Summary

Twist Bioscience Corp President and COO Patrick John Finn reported an open-market sale of 4,294 shares of common stock at an average price of $46.7098 per share. The transaction was a mandated “sell to cover” to satisfy tax withholding tied to vesting restricted stock units, not a discretionary trade. After this sale, Finn directly owns 284,129 Twist Bioscience shares, which includes shares acquired through the company’s employee stock purchase plan.

Insider Trade Summary

Net Seller: 4,294 shares

Net Sell 1 txn

Insider Finn Patrick John

Role President and COO

Sold 4,294 shs ($201K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,294	$46.7098	$201K

Holdings After Transaction: Common Stock — 284,129 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
2. F2. Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Twist Bioscience (TWST) President and COO Patrick John Finn report in this Form 4?

Patrick John Finn reported selling 4,294 shares of Twist Bioscience common stock. The sale was an automatic “sell to cover” transaction used to satisfy tax withholding obligations from vesting restricted stock units, rather than a discretionary decision to reduce his investment position.

Why did Patrick John Finn sell 4,294 Twist Bioscience (TWST) shares?

The 4,294 shares were sold to cover tax withholding obligations from vesting restricted stock units. Twist Bioscience’s equity plans mandate this “sell to cover” approach, meaning the transaction was driven by tax requirements and plan elections, not by Finn’s independent trading decision.

At what price were the 4,294 Twist Bioscience (TWST) shares sold by the COO?

The 4,294 Twist Bioscience shares were sold at an average price of $46.7098 per share. This price reflects the open-market execution for the mandated tax-withholding sale associated with the vesting of restricted stock units under the company’s equity incentive plans.

How many Twist Bioscience (TWST) shares does Patrick John Finn own after this transaction?

After the sale, Patrick John Finn directly owns 284,129 Twist Bioscience shares. This total includes shares acquired through the company’s Employee Stock Purchase Plan in exempt transactions under Rule 16b-3, as noted in the Form 4 footnotes provided with the filing.

Was Patrick John Finn’s Twist Bioscience (TWST) stock sale a discretionary trade?

The reported stock sale was not a discretionary trade by Patrick John Finn. It was a required “sell to cover” transaction under Twist Bioscience’s equity incentive plans, executed solely to fund tax withholding obligations triggered by restricted stock unit vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 04:05 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Finn Patrick John

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		S		4,294(1)	D	$46.7098	284,129(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

2. Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.